(ABEV) Ambev - Overview
Exchange: NYSE •
Country: Brazil •
Currency: USD •
Type: Common Stock •
ISIN: US02319V1035
Stock: Beer, Soft Drinks, Beverages
Total Rating 67
Risk 80
Buy Signal -1.01
| Risk 5d forecast | |
|---|---|
| Volatility | 26.3% |
| Relative Tail Risk | -1.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 31.95 |
| Character TTM | |
|---|---|
| Beta | 0.124 |
| Beta Downside | -0.180 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.91% |
| CAGR/Max DD | 0.27 |
EPS (Earnings per Share)
Revenue
Description: ABEV Ambev March 04, 2026
Ambev S.A. (ABEV) is a Brazilian beverage company. It produces and distributes beer, soft drinks, and other non-alcoholic beverages across Brazil, Central and South America, and Canada. The company operates in the consumer staples sector, which is generally characterized by stable demand.
ABEVs product portfolio includes well-known brands like Brahma and Skol. The company utilizes a broad distribution network to reach supermarkets, retailers, and other distributors. This business model relies on extensive supply chain management and brand recognition. To understand ABEVs competitive standing and market share within these regions, further research on platforms like ValueRay is recommended.
Headlines to watch out for
- Brazilian beer consumption directly impacts revenue
- Currency fluctuations affect international sales and costs
- Commodity price volatility influences production expenses
- Regulatory changes in alcohol sales pose risk
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 15.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 0.25 > 1.0 |
| NWC/Revenue: -1.95% < 20% (prev 5.33%; Δ -7.28% < -1%) |
| CFO/TA 0.16 > 3% & CFO 24.42b > Net Income 15.50b |
| Net Debt (-13.29b) to EBITDA (26.32b): -0.50 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.66b) vs 12m ago -0.97% < -2% |
| Gross Margin: 51.42% > 18% (prev 0.51%; Δ 5.09k% > 0.5%) |
| Asset Turnover: 56.82% > 50% (prev 55.05%; Δ 1.77% > 0%) |
| Interest Coverage Ratio: 38.47 > 6 (EBITDA TTM 26.32b / Interest Expense TTM 510.1m) |
Altman Z'' 2.78
| A: -0.01 (Total Current Assets 43.88b - Total Current Liabilities 45.60b) / Total Assets 148.11b |
| B: 0.12 (Retained Earnings 18.04b / Total Assets 148.11b) |
| C: 0.13 (EBIT TTM 19.62b / Avg Total Assets 155.31b) |
| D: 1.53 (Book Value of Equity 90.86b / Total Liabilities 59.34b) |
| Altman-Z'' Score: 2.78 = A |
Beneish M -3.01
| DSRI: 1.05 (Receivables 10.23b/9.85b, Revenue 88.24b/89.45b) |
| GMI: 1.00 (GM 51.42% / 51.24%) |
| AQI: 1.07 (AQ_t 0.52 / AQ_t-1 0.48) |
| SGI: 0.99 (Revenue 88.24b / 89.45b) |
| TATA: -0.06 (NI 15.50b - CFO 24.42b) / TA 148.11b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of ABEV shares?
As of March 19, 2026, the stock is trading at USD 2.92 with a total of 14,857,699 shares traded.
Over the past week, the price has changed by -5.35%, over one month by -7.21%, over three months by +20.56% and over the past year by +29.76%.
Over the past week, the price has changed by -5.35%, over one month by -7.21%, over three months by +20.56% and over the past year by +29.76%.
Is ABEV a buy, sell or hold?
Ambev has received a consensus analysts rating of 3.42.
Therefor, it is recommend to hold ABEV.
- StrongBuy: 2
- Buy: 2
- Hold: 7
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ABEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.1 | 6.2% |
| Analysts Target Price | 3.1 | 6.2% |
ABEV Fundamental Data Overview March 19, 2026
Market Cap BRL = 235.64b (45.38b USD * 5.1929 USD.BRL)
P/E Trailing = 15.1053
P/E Forward = 15.0376
P/S = 0.5142
P/B = 2.7663
P/EG = 2.1743
Revenue TTM = 88.24b BRL
EBIT TTM = 19.62b BRL
EBITDA TTM = 26.32b BRL
Long Term Debt = 256.9m BRL (from longTermDebt, last quarter)
Short Term Debt = 1.17b BRL (from shortTermDebt, last quarter)
Debt = 5.35b BRL (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.29b BRL (from netDebt column, last quarter)
Enterprise Value = 220.67b BRL (235.64b + Debt 5.35b - CCE 20.32b)
Interest Coverage Ratio = 38.47 (Ebit TTM 19.62b / Interest Expense TTM 510.1m)
EV/FCF = 11.13x (Enterprise Value 220.67b / FCF TTM 19.83b)
FCF Yield = 8.99% (FCF TTM 19.83b / Enterprise Value 220.67b)
FCF Margin = 22.48% (FCF TTM 19.83b / Revenue TTM 88.24b)
Net Margin = 17.57% (Net Income TTM 15.50b / Revenue TTM 88.24b)
Gross Margin = 51.42% ((Revenue TTM 88.24b - Cost of Revenue TTM 42.86b) / Revenue TTM)
Gross Margin QoQ = 52.63% (prev 51.46%)
Tobins Q-Ratio = 1.49 (Enterprise Value 220.67b / Total Assets 148.11b)
Interest Expense / Debt = -16.15% (Interest Expense -864.1m / Debt 5.35b)
Taxrate = 23.64% (1.40b / 5.93b)
NOPAT = 14.98b (EBIT 19.62b * (1 - 23.64%))
Current Ratio = 0.96 (Total Current Assets 43.88b / Total Current Liabilities 45.60b)
Debt / Equity = 0.06 (Debt 5.35b / totalStockholderEquity, last quarter 87.91b)
Debt / EBITDA = -0.50 (Net Debt -13.29b / EBITDA 26.32b)
Debt / FCF = -0.67 (Net Debt -13.29b / FCF TTM 19.83b)
Total Stockholder Equity = 91.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.98% (Net Income 15.50b / Total Assets 148.11b)
RoE = 16.90% (Net Income TTM 15.50b / Total Stockholder Equity 91.74b)
RoCE = 21.33% (EBIT 19.62b / Capital Employed (Equity 91.74b + L.T.Debt 256.9m))
RoIC = 16.02% (NOPAT 14.98b / Invested Capital 93.54b)
WACC = 6.23% (E(235.64b)/V(240.99b) * Re(6.37%) + (debt cost/tax rate unavailable))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.54%
[DCF] Terminal Value 85.97% ; FCFF base≈20.44b ; Y1≈22.53b ; Y5≈28.98b
[DCF] Fair Price = 50.18 (EV 770.30b - Net Debt -13.29b = Equity 783.59b / Shares 15.62b; r=6.23% [WACC]; 5y FCF grow 11.74% → 2.90% )
EPS Correlation: 53.02 | EPS CAGR: 68.02% | SUE: 4.0 | # QB: 1
Revenue Correlation: 57.96 | Revenue CAGR: 8.23% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.03 | Chg7d=-0.000 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.19 | Chg7d=-0.001 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=0.21 | Chg7d=-0.001 | Chg30d=-0.007 | Revisions Net=+0 | Growth EPS=+10.8% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.3% (Discount Rate 7.9% - Earnings Yield 6.6%)
[Growth] Growth Spread = +3.4% (Analyst 4.7% - Implied 1.3%)
P/E Trailing = 15.1053
P/E Forward = 15.0376
P/S = 0.5142
P/B = 2.7663
P/EG = 2.1743
Revenue TTM = 88.24b BRL
EBIT TTM = 19.62b BRL
EBITDA TTM = 26.32b BRL
Long Term Debt = 256.9m BRL (from longTermDebt, last quarter)
Short Term Debt = 1.17b BRL (from shortTermDebt, last quarter)
Debt = 5.35b BRL (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.29b BRL (from netDebt column, last quarter)
Enterprise Value = 220.67b BRL (235.64b + Debt 5.35b - CCE 20.32b)
Interest Coverage Ratio = 38.47 (Ebit TTM 19.62b / Interest Expense TTM 510.1m)
EV/FCF = 11.13x (Enterprise Value 220.67b / FCF TTM 19.83b)
FCF Yield = 8.99% (FCF TTM 19.83b / Enterprise Value 220.67b)
FCF Margin = 22.48% (FCF TTM 19.83b / Revenue TTM 88.24b)
Net Margin = 17.57% (Net Income TTM 15.50b / Revenue TTM 88.24b)
Gross Margin = 51.42% ((Revenue TTM 88.24b - Cost of Revenue TTM 42.86b) / Revenue TTM)
Gross Margin QoQ = 52.63% (prev 51.46%)
Tobins Q-Ratio = 1.49 (Enterprise Value 220.67b / Total Assets 148.11b)
Interest Expense / Debt = -16.15% (Interest Expense -864.1m / Debt 5.35b)
Taxrate = 23.64% (1.40b / 5.93b)
NOPAT = 14.98b (EBIT 19.62b * (1 - 23.64%))
Current Ratio = 0.96 (Total Current Assets 43.88b / Total Current Liabilities 45.60b)
Debt / Equity = 0.06 (Debt 5.35b / totalStockholderEquity, last quarter 87.91b)
Debt / EBITDA = -0.50 (Net Debt -13.29b / EBITDA 26.32b)
Debt / FCF = -0.67 (Net Debt -13.29b / FCF TTM 19.83b)
Total Stockholder Equity = 91.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.98% (Net Income 15.50b / Total Assets 148.11b)
RoE = 16.90% (Net Income TTM 15.50b / Total Stockholder Equity 91.74b)
RoCE = 21.33% (EBIT 19.62b / Capital Employed (Equity 91.74b + L.T.Debt 256.9m))
RoIC = 16.02% (NOPAT 14.98b / Invested Capital 93.54b)
WACC = 6.23% (E(235.64b)/V(240.99b) * Re(6.37%) + (debt cost/tax rate unavailable))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.54%
[DCF] Terminal Value 85.97% ; FCFF base≈20.44b ; Y1≈22.53b ; Y5≈28.98b
[DCF] Fair Price = 50.18 (EV 770.30b - Net Debt -13.29b = Equity 783.59b / Shares 15.62b; r=6.23% [WACC]; 5y FCF grow 11.74% → 2.90% )
EPS Correlation: 53.02 | EPS CAGR: 68.02% | SUE: 4.0 | # QB: 1
Revenue Correlation: 57.96 | Revenue CAGR: 8.23% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.03 | Chg7d=-0.000 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.19 | Chg7d=-0.001 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=0.21 | Chg7d=-0.001 | Chg30d=-0.007 | Revisions Net=+0 | Growth EPS=+10.8% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.3% (Discount Rate 7.9% - Earnings Yield 6.6%)
[Growth] Growth Spread = +3.4% (Analyst 4.7% - Implied 1.3%)